deciphera®
a member of ONO PHARMA
MEDICAL AFFAIRS

A complete listing of sites and additional information for this clinical trial can be found at **clinicaltrials.gov/study/NCT06966024**.

For more information, email
medicalinformation@deciphera.com

DCC-2812

A Phase 1, Open-label Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

deciphera®
a member of ONO PHARMA
MEDICAL AFFAIRS

DCPH-M00904v3 05/26

DCC-2812 (an oral, selective and potent activator of GCN2 kinase activity and the integrated stress response) is an investigational drug that has not been approved by the US FDA, European Commission, or any other regulatory agency.

Study Design

Phase 1, multicenter, open-label, study of DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer



*Depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.

Primary Outcome Measures

- Number of participants with dose-limiting toxicities (DLTs)
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
- Number of participants with dose reduction, interruption, or discontinuation of study drug due to TEAEs

Secondary Outcome Measures

- Radiographic objective response rate (rORR) per RECIST v1.1
- Radiographic duration of response (rDOR) per RECIST v1.1
- PK properties

Inclusion Criteria

- Have confirmed advanced or metastatic renal cell carcinoma, urothelial cancer, or castration-resistant prostate cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes

Exclusion Criteria

- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days of the first dose of study drug

DCC-2812 (an oral, selective and potent activator of GCN2 kinase activity and the integrated stress response) is an investigational drug that has not been approved by the US FDA, European Commission, or any other regulatory agency.